Market Cap 1.06B
Revenue (ttm) 0.00
Net Income (ttm) -3.35M
EPS (ttm) N/A
PE Ratio 8.33
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -1.72
Volume 856,100
Avg Vol 1,074,550
Day's Range N/A - N/A
Shares Out 72.00M
Stochastic %K 83%
Beta 2.53
Analysts Strong Sell
Price Target $43.67

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 676 5000
Address:
The Omeros Building, 201 Elliott Avenue West, Seattle, United States
DragonAlgo
DragonAlgo Apr. 30 at 1:19 PM
🐉 $OMER CALL — DragonAlgo® Signal Contract: OMER CALL Expiry: 2026-05-15 | Strike: $15.00 | Type: CALL Option Plan (premium): Entry: $1.06 Stop: $0.76 TP1: $1.38 TP2: $1.80 TP3: $2.54 🔗 https://dragonalgo.com
0 · Reply
resq1
resq1 Apr. 30 at 1:00 PM
$OMER seems like this is dated intentionally right after some game changing news is anticipated. Possible M&A, on top of EMA. Approval Anticipated
0 · Reply
Abaco24
Abaco24 Apr. 30 at 12:14 PM
$OMER Dear Fellow Shareholder: You are cordially invited to attend the 2026 Annual Meeting of Shareholders of Omeros Corporation. We plan to hold an entirely virtual meeting this year via live webcast on the Internet on Thursday, June 18, 2026, at 10:00 a.m. Pacific time. You will be able to attend the meeting, vote and submit your questions via the Internet at www.virtualshareholdermeeting.com/OMER2026.
0 · Reply
Abaco24
Abaco24 Apr. 30 at 12:11 PM
$OMER What is SEC Form DEF 14A? SEC Form DEF 14A, also called a definitive proxy statement, is intended to furnish security holders with adequate information to be able to vote confidently at an upcoming shareholders’ meeting. Form DEF 14A is most commonly used with an annual meeting proxy and filed in advance of a company’s annual meeting. The statement must be filed with the Securities and Exchange Commission (SEC) by or on behalf of the firm soliciting shareholder votes. Under The Securities and Exchange Act of 1934, Form DEF 14A ensures that shareholders receive crucial voting information including when and where a shareholder meeting will be held; voting information and procedures; revocability of proxies; procedure for submitting stockholder proposals; background on the company’s nominated directors; top shareholders and holding details; potential conflicts of interest among directors; board and executive compensation, with details including perquisites; audit fees and committee.
0 · Reply
jmmoore4
jmmoore4 Apr. 30 at 1:14 AM
$OMER News tomorrow? 🤔
0 · Reply
Arad288
Arad288 Apr. 29 at 7:19 PM
$OMER 625,000 shares traded, pretty quiet around here . Go Omer
2 · Reply
TRYII
TRYII Apr. 29 at 3:03 PM
$OMER As oil continues to rip and eventually impact industry after industry Wall Street money is going to find OMER more and more attractive. Rotation in 3,2,1......
0 · Reply
resq1
resq1 Apr. 29 at 12:37 PM
1 · Reply
HawgTrader
HawgTrader Apr. 29 at 11:53 AM
$OMER break 15 today.
1 · Reply
costrexx
costrexx Apr. 29 at 11:04 AM
$OMER provention bio was $6.70 just before it was bought out at $25. I wonder at what price would dr D consider selling Omeros. The goal of advancing the pipeline quicker would be accomplished by being absorbed into a large company with unlimited resources. Using the proventiok model, the purchase price of omerod would be around $55 https://www.reuters.com/markets/deals/frances-sanofi-acquire-us-based-provention-bio-29-bln-2023-03-13/
0 · Reply
Latest News on OMER
Omeros Earnings Call Transcript: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 4 weeks ago

Omeros Earnings Call Transcript: Q4 2025


Omeros Announces First Commercial Sales of YARTEMLEA®

Jan 27, 2026, 9:00 AM EST - 3 months ago

Omeros Announces First Commercial Sales of YARTEMLEA®


Omeros prices transplant complication drug at $36,000 per dose

Jan 7, 2026, 6:50 PM EST - 4 months ago

Omeros prices transplant complication drug at $36,000 per dose


Omeros Transcript: FDA Announcement

Jan 7, 2026, 4:30 PM EST - 4 months ago

Omeros Transcript: FDA Announcement


Gold Edges Lower; Omeros Shares Jump

Dec 24, 2025, 12:21 PM EST - 4 months ago

Gold Edges Lower; Omeros Shares Jump

AAAU BAR DBP GLD GLDM IAU OUNZ


Omeros Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 5 months ago

Omeros Earnings Call Transcript: Q3 2025


Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 13, 2025, 4:11 PM EST - 5 months ago

Omeros Corporation Reports Third Quarter 2025 Financial Results


Omeros Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 9 months ago

Omeros Earnings Call Transcript: Q2 2025


Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:02 PM EDT - 9 months ago

Omeros Corporation Reports Second Quarter 2025 Financial Results


Omeros Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q1 2025


Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Apr 11, 2025, 3:06 PM EDT - 1 year ago

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight


Omeros Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q4 2024


Omeros Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Omeros Earnings Call Transcript: Q3 2024


Omeros Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q2 2024


Omeros Earnings Call Transcript: Q1 2024

May 15, 2024, 4:30 PM EDT - 2 years ago

Omeros Earnings Call Transcript: Q1 2024


Omeros Earnings Call Transcript: Q4 2023

Apr 1, 2024, 4:30 PM EDT - 2 years ago

Omeros Earnings Call Transcript: Q4 2023


Omeros Earnings Call Transcript: Q3 2023

Nov 9, 2023, 4:30 PM EST - 2 years ago

Omeros Earnings Call Transcript: Q3 2023


Omeros Earnings Call Transcript: Q2 2023

Aug 9, 2023, 8:30 AM EDT - 2 years ago

Omeros Earnings Call Transcript: Q2 2023


Omeros Earnings Call Transcript: Q1 2023

May 9, 2023, 4:30 PM EDT - 3 years ago

Omeros Earnings Call Transcript: Q1 2023


Omeros Earnings Call Transcript: Q4 2022

Mar 13, 2023, 4:30 PM EDT - 3 years ago

Omeros Earnings Call Transcript: Q4 2022


Omeros Earnings Call Transcript: Q3 2022

Nov 9, 2022, 2:00 PM EST - 3 years ago

Omeros Earnings Call Transcript: Q3 2022


DragonAlgo
DragonAlgo Apr. 30 at 1:19 PM
🐉 $OMER CALL — DragonAlgo® Signal Contract: OMER CALL Expiry: 2026-05-15 | Strike: $15.00 | Type: CALL Option Plan (premium): Entry: $1.06 Stop: $0.76 TP1: $1.38 TP2: $1.80 TP3: $2.54 🔗 https://dragonalgo.com
0 · Reply
resq1
resq1 Apr. 30 at 1:00 PM
$OMER seems like this is dated intentionally right after some game changing news is anticipated. Possible M&A, on top of EMA. Approval Anticipated
0 · Reply
Abaco24
Abaco24 Apr. 30 at 12:14 PM
$OMER Dear Fellow Shareholder: You are cordially invited to attend the 2026 Annual Meeting of Shareholders of Omeros Corporation. We plan to hold an entirely virtual meeting this year via live webcast on the Internet on Thursday, June 18, 2026, at 10:00 a.m. Pacific time. You will be able to attend the meeting, vote and submit your questions via the Internet at www.virtualshareholdermeeting.com/OMER2026.
0 · Reply
Abaco24
Abaco24 Apr. 30 at 12:11 PM
$OMER What is SEC Form DEF 14A? SEC Form DEF 14A, also called a definitive proxy statement, is intended to furnish security holders with adequate information to be able to vote confidently at an upcoming shareholders’ meeting. Form DEF 14A is most commonly used with an annual meeting proxy and filed in advance of a company’s annual meeting. The statement must be filed with the Securities and Exchange Commission (SEC) by or on behalf of the firm soliciting shareholder votes. Under The Securities and Exchange Act of 1934, Form DEF 14A ensures that shareholders receive crucial voting information including when and where a shareholder meeting will be held; voting information and procedures; revocability of proxies; procedure for submitting stockholder proposals; background on the company’s nominated directors; top shareholders and holding details; potential conflicts of interest among directors; board and executive compensation, with details including perquisites; audit fees and committee.
0 · Reply
jmmoore4
jmmoore4 Apr. 30 at 1:14 AM
$OMER News tomorrow? 🤔
0 · Reply
Arad288
Arad288 Apr. 29 at 7:19 PM
$OMER 625,000 shares traded, pretty quiet around here . Go Omer
2 · Reply
TRYII
TRYII Apr. 29 at 3:03 PM
$OMER As oil continues to rip and eventually impact industry after industry Wall Street money is going to find OMER more and more attractive. Rotation in 3,2,1......
0 · Reply
resq1
resq1 Apr. 29 at 12:37 PM
1 · Reply
HawgTrader
HawgTrader Apr. 29 at 11:53 AM
$OMER break 15 today.
1 · Reply
costrexx
costrexx Apr. 29 at 11:04 AM
$OMER provention bio was $6.70 just before it was bought out at $25. I wonder at what price would dr D consider selling Omeros. The goal of advancing the pipeline quicker would be accomplished by being absorbed into a large company with unlimited resources. Using the proventiok model, the purchase price of omerod would be around $55 https://www.reuters.com/markets/deals/frances-sanofi-acquire-us-based-provention-bio-29-bln-2023-03-13/
0 · Reply
hmb
hmb Apr. 29 at 1:35 AM
$OMER good chance news comes out before another record breaking earnings. Could see $30 sooner than we think
0 · Reply
nick39
nick39 Apr. 29 at 12:38 AM
$OMER https://seekingalpha.com/news/4571072-omeros-expects-yartemlea-to-be-financially-self-sustaining-in-2026-and-targets-positive-cash?feed_item_type=news&fr=1
1 · Reply
nick39
nick39 Apr. 29 at 12:37 AM
$OMER https://seekingalpha.com/news/4571072-omeros-expects-yartemlea-to-be-financially-self-sustaining-in-2026-and-targets-positive-cash?feed_item_type=news&fr=1
0 · Reply
costrexx
costrexx Apr. 28 at 10:37 PM
$OMER looks like all of the bears have died out for now. This happened to provention Bio just before it was bought out. I don’t think it will be bought out soon but it’s a strange feeling to see no trolls
2 · Reply
4Reel
4Reel Apr. 28 at 10:26 PM
$OMER it has made this steady run up while bios have did terrible over the last week too. Thats strength. Xbi should be at support so looking for the sector as a whole to bounce now which is good here
0 · Reply
Caesar65
Caesar65 Apr. 28 at 9:35 PM
$OMER EC coming in a few weeks. Feels like we have some momentum heading in. Wouldnt surprise me if we get near 52 Week high in the 17's these upcoming weeks. Obviously a strong earnings report should get us to the long awaited 20 everyone has been talking about. Just feels for once all stars are aligned.
0 · Reply
hmb
hmb Apr. 28 at 8:42 PM
$OMER down .07 Shorts are so cooked.
0 · Reply
Hawkstwit
Hawkstwit Apr. 28 at 8:00 PM
$OMER not too shabby!
0 · Reply
ThreeGirls
ThreeGirls Apr. 28 at 7:06 PM
$OMER Part I Any short squeeze that may be coming will be muted compared to what many expect. Why? Because only about half of the 17M shares held short will participate in a squeeze. Much talk on OMER social media about the big squeeze coming especially when you consider that 17M shares are held short representing about 24% of the shares outstanding. But it is VERY LIKELY, that as much as half of the shares held short are held by the debt holders of the $70M, 11.1M share, 2029 convertible debt and as such, their short positions are considered “mechanical hedges” vs. the traditional “directional” shorts that are betting on a drop in share price. These two different types of “shorts” behave differently and have differing impact on the underlying SP. In fact the shares held short by the debt holders will have VERY LITTLE input to a short squeeze, leaving only the “directional shorts” for the potential to squeeze, about half the 17M short shares In my reply I explain why
4 · Reply
tau72
tau72 Apr. 28 at 6:00 PM
$OMER Good ER + EMA approval (mid-2026) = 20+ easy. GLTA
0 · Reply
4Reel
4Reel Apr. 28 at 5:52 PM
$OMER strongest thoroughbred in my portfolio, strong even when micros are getting crushed
0 · Reply
MarcJ55
MarcJ55 Apr. 28 at 4:53 PM
$OMER Targeting the Lectin Pathway in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy: Narsoplimab Enters the Arena https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V23.3.202633/567864
0 · Reply